MX2020000576A - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX2020000576A
MX2020000576A MX2020000576A MX2020000576A MX2020000576A MX 2020000576 A MX2020000576 A MX 2020000576A MX 2020000576 A MX2020000576 A MX 2020000576A MX 2020000576 A MX2020000576 A MX 2020000576A MX 2020000576 A MX2020000576 A MX 2020000576A
Authority
MX
Mexico
Prior art keywords
sup
formula
chemical compounds
compound
relates
Prior art date
Application number
MX2020000576A
Other languages
English (en)
Spanish (es)
Inventor
David Thomas Davies
Simon Leiris
Nicolas Sprynski
Martin Everett
Magdalena Zalacain
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17305973.4A external-priority patent/EP3431474A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of MX2020000576A publication Critical patent/MX2020000576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020000576A 2017-07-21 2018-07-20 Compuestos quimicos. MX2020000576A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305973.4A EP3431474A1 (en) 2017-07-21 2017-07-21 Chemical compounds
EP18290003 2018-01-08
EP18150903 2018-01-09
PCT/EP2018/069827 WO2019016393A1 (en) 2017-07-21 2018-07-20 CHEMICAL COMPOUNDS

Publications (1)

Publication Number Publication Date
MX2020000576A true MX2020000576A (es) 2020-09-10

Family

ID=62952102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000576A MX2020000576A (es) 2017-07-21 2018-07-20 Compuestos quimicos.

Country Status (15)

Country Link
US (2) US11299467B2 (https=)
EP (1) EP3655405B1 (https=)
JP (1) JP2020528412A (https=)
KR (1) KR20200030584A (https=)
CN (2) CN115745910B (https=)
AU (1) AU2018304907B2 (https=)
BR (1) BR112020001327A2 (https=)
CA (1) CA3070036A1 (https=)
ES (1) ES2946917T3 (https=)
IL (1) IL272174A (https=)
MA (1) MA49623A (https=)
MX (1) MX2020000576A (https=)
SG (1) SG11202000217QA (https=)
WO (1) WO2019016393A1 (https=)
ZA (1) ZA202000529B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN110878032B (zh) * 2019-10-31 2022-03-15 苏州诚和医药化学有限公司 一种n-苄基乙脒盐酸盐的合成方法
CN110713459A (zh) * 2019-12-04 2020-01-21 西南大学 一类喹啉酮富马来酰胺衍生物的设计合成与应用
KR102874744B1 (ko) 2020-03-12 2025-10-22 주식회사 엘지에너지솔루션 에너지 밀도가 향상된 전지 모듈 및 이를 포함하는 전지 팩
CN115745838B (zh) * 2022-10-27 2023-12-22 苏州诚和医药化学有限公司 一种脒类化合物及n-苄基乙脒盐酸盐的合成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1053833A1 (zh) 2000-04-27 2003-11-07 Abbott Laboratories 取代苯基法呢基转移酶抑制剂
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
KR20090090406A (ko) 2000-12-18 2009-08-25 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 염증성 사이토카인 생산 유리 억제제
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
US6806265B2 (en) 2002-05-16 2004-10-19 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004026264A2 (en) * 2002-09-20 2004-04-01 Genelabs Technologies, Inc. Novel aromatic compounds possessing antifungal or antibacterial activity
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
CN1810777B (zh) * 2005-01-24 2010-09-29 上海东浩医药生物企业有限公司 一类治疗或预防细菌感染的化合物及其制备方法和用途
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
US8039502B2 (en) * 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
CA2698847A1 (en) 2007-09-04 2009-03-12 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
EP2231655B1 (en) 2007-11-13 2011-08-31 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain
CN101910166A (zh) 2007-11-13 2010-12-08 沃泰克斯药物股份有限公司 用作钠离子通道调节剂的杂环衍生物
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
WO2009118596A2 (en) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
EP2297097A2 (en) 2008-06-11 2011-03-23 Irm Llc Compounds and compositions useful for the treatment of malaria
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
SG10201702247SA (en) 2009-01-12 2017-04-27 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome
WO2010084402A2 (en) 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US9005579B2 (en) 2010-01-05 2015-04-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
CA2794676A1 (en) 2010-03-29 2011-10-06 Piramal Enterprises Limited Cytokine inhibitors
RU2610091C2 (ru) 2011-06-17 2017-02-07 Астразенека Аб (2S,5R)-5-[(бензилокси)амино]пиперидин-2-карбоксамид
CA2846107C (en) 2011-09-13 2016-06-21 Wockhardt Limited Nitrogen containing compounds and their use
MX2014008763A (es) * 2012-01-18 2015-04-13 Cellceutix Corp Compuestos y metodos para tratar infecciones por candidosis y aspergillus.
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
WO2014144606A2 (en) 2013-03-15 2014-09-18 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US9540389B2 (en) * 2013-05-03 2017-01-10 Microbiotix, Inc. Antimicrobial potentiators
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
AU2014268477A1 (en) 2013-05-24 2015-11-12 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
GB201310542D0 (en) * 2013-06-13 2013-07-31 Antabio Sas Compounds
ES2901198T3 (es) 2013-10-08 2022-03-21 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas
EP3105231A1 (en) 2014-01-21 2016-12-21 Wockhardt Limited A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane
KR20160115946A (ko) 2014-02-03 2016-10-06 욱크하르트 리미티드 (2s,5r)-1,6-다이아자-바이사이클로[3.2.1]옥테인-2-카보나이트릴-7-옥소-6-(설포옥시)-모노 소듐 염의 제조 공정
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds

Also Published As

Publication number Publication date
CN110446708B (zh) 2022-12-02
WO2019016393A1 (en) 2019-01-24
CA3070036A1 (en) 2019-01-24
SG11202000217QA (en) 2020-02-27
IL272174A (en) 2020-03-31
MA49623A (fr) 2021-03-17
JP2020528412A (ja) 2020-09-24
CN115745910B (zh) 2025-05-27
EP3655405B1 (en) 2023-06-07
US11299467B2 (en) 2022-04-12
ES2946917T3 (es) 2023-07-27
US20200339526A1 (en) 2020-10-29
AU2018304907A1 (en) 2020-02-06
US20220315546A1 (en) 2022-10-06
AU2018304907B2 (en) 2022-11-24
ZA202000529B (en) 2023-07-26
EP3655405C0 (en) 2023-06-07
CN115745910A (zh) 2023-03-07
KR20200030584A (ko) 2020-03-20
CN110446708A (zh) 2019-11-12
BR112020001327A2 (pt) 2020-08-11
EP3655405A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2020000576A (es) Compuestos quimicos.
GEAP202215535A (en) Compounds
MX392515B (es) Compuestos inhibidores de beta-lactamasa
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
PH12018502012A1 (en) Griseofulvin compound
MX2019006768A (es) Peptidos antimicrobianos.
EA200970534A1 (ru) Антибактериальные производные хинолина
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
MY205944A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
PH12022550983A1 (en) Novel substituted condensed ring compound
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
MX2021003481A (es) Compuesto heterociclico.
NZ737820A (en) Mannose derivatives for treating bacterial infections